Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 310-316

  Sadiq, Mohammad Ali ^a   Hanout, Mostafa ^a   Sarwar, Salman ^a   Hassan, Muhammad ^a   Agarwal, Aniruddha ^a   Sepah, Yasir Jamal ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PLATELET DERIVED GROWTH FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMAN; RETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RETINAL NEOVASCULARIZATION;

EID: 84947267492     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000438953     Document Type: Article

References (32)

1. Demoulin JB, Montano-Almendras CP: Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012; 2:44-56.
2. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-1312.
3. Edqvist PH, Niklasson M, Vidal-Sanz M, Hallbook F, Forsberg-Nilsson K: Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation. PLoS One 2012; 7:e42488.
4. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79:1283-1316.
5. Alvarez RH, Kantarjian HM, Cortes JE: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81:1241-1257.
6. Fruttiger M, Calver AR, Richardson WD: Platelet-derived growth factor is constitutively secreted from neuronal cell bodies but not from axons. Curr Biol 2000; 10:1283-1286.
7. Reneker LW, Overbeek PA: Lens-specific expression of PDGF-A in transgenic mice results in retinal astrocytic hamartomas. Invest Ophthalmol Vis Sci 1996; 37:2455-2466.
8. Tang Z, Arjunan P, Lee C, Li Y, Kumar A, Hou X, et al. Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med 2010; 207:867-880.
9. Wang Y, Abu-Asab MS, Yu CR, Tang Z, Shen D, Tuo J, et al. Platelet-derived growth factor (PDGF)-C inhibits neuroretinal apoptosis in a murine model of focal retinal degeneration. Lab Invest 2014; 94:674-682.
10. Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277:242-245.
11. Mudhar HS, Pollock RA, Wang C, Stiles CD, Richardson WD: PDGF and its receptors in the developing rodent retina and optic nerve. Development 1993; 118:539-552.
12. Trojanowska M: Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008; 47(suppl 5):v2-v4.
13. Grimminger F, Schermuly RT: PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010; 661:435-446.
14. Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun 2013; 4:2129.
15. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66:8715-8721.
16. Crino L, Metro G: Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 2014; 23:79-91.
17. Michaelson IC: The mode of development of the vascular system of the retina. With some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68:137-180.
18. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142:1119-1130.
19. Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, et al. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes 1996; 45:507-512.
20. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 2000; 157:995-1005.
21. Koyama N, Watanabe S, Tezuka M, Morisaki N, Saito Y, Yoshida S: Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor. J Cell Physiol 1994; 158:1-6.
22. Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 2000; 108:106-109.
23. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994; 35:3649-3663.
24. Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, et al. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2014; 17:553-562.
25. A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects with Neovascular Age-Related Macular Degeneration. US National Institutes of Health, 2007, http://clinicaltrials.gov/show/NCT00569140 (accessed May 11, 2015).
26. Jordi M: Inhibiting VEGF and PDGF to treat AMD. Rev Ophthalmol, 2011, http://www.revophth.com/content/d/retinal-insider/c/29979/ (accessed May 11, 2015).
27. Ophthotech C: A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration. US National Institutes of Health, 2010, http://clinicaltrials.gov/ct2/show/NCT01089517 (accessed May 11, 2015).
28. Dugel PU: Anti-PDGF combination therapy in neovascular age-related macular degeneration: results of a phase 2b study. Retina Today, 2013, http://retinatoday.com/2013/03/anti-pdgf-combination-Dherapy-in-neovascular-Age-related-macular-degeneration-results-of-A-phase-2b-study/ (accessed May 11, 2015).
29. A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination with Lucentis® Compared to Lucentis® Monotherapy. US National Institutes of Health, 2013, http://clinicaltrials.gov/ct2/show/record/NCT01940900 (accessed May 11, 2015).
30. A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination with Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy. US National Institutes of Health, 2013, https://clinicaltrials.gov/ct2/show/NCT01940887 (accessed May 11, 2015).
31. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398.
32. Betsholtz C: Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004; 15:215-228.